These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1026 related articles for article (PubMed ID: 21802134)

  • 1. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.
    Nelson PK; Mathers BM; Cowie B; Hagan H; Des Jarlais D; Horyniak D; Degenhardt L
    Lancet; 2011 Aug; 378(9791):571-83. PubMed ID: 21802134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.
    Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S
    Lancet Glob Health; 2017 Dec; 5(12):e1192-e1207. PubMed ID: 29074409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review.
    Degenhardt L; Webb P; Colledge-Frisby S; Ireland J; Wheeler A; Ottaviano S; Willing A; Kairouz A; Cunningham EB; Hajarizadeh B; Leung J; Tran LT; Price O; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Grebely J
    Lancet Glob Health; 2023 May; 11(5):e659-e672. PubMed ID: 36996857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global estimates of prevalence of HCV infection among injecting drug users.
    Aceijas C; Rhodes T
    Int J Drug Policy; 2007 Oct; 18(5):352-8. PubMed ID: 17854722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
    Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
    BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.
    Mathers BM; Degenhardt L; Ali H; Wiessing L; Hickman M; Mattick RP; Myers B; Ambekar A; Strathdee SA;
    Lancet; 2010 Mar; 375(9719):1014-28. PubMed ID: 20189638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
    Devi KhS; Brajachand N; Singh HL; Singh YM
    J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013.
    Degenhardt L; Charlson F; Stanaway J; Larney S; Alexander LT; Hickman M; Cowie B; Hall WD; Strang J; Whiteford H; Vos T
    Lancet Infect Dis; 2016 Dec; 16(12):1385-1398. PubMed ID: 27665254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.
    Rai RR; Mathur A; Mathur D; Udawat HP; Nepalia S; Nijhawan S; Mathur A
    Trop Gastroenterol; 2007; 28(1):19-23. PubMed ID: 17896605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.
    Hahné SJ; Veldhuijzen IK; Wiessing L; Lim TA; Salminen M; Laar Mv
    BMC Infect Dis; 2013 Apr; 13():181. PubMed ID: 23597411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study on the blood-borne virus co-infection and T lymphocyte subset among intravenous drug users.
    Li JR; Gong RY; Tian KL; Wang J; Wang YX; Huang HJ
    World J Gastroenterol; 2007 Apr; 13(16):2357-62. PubMed ID: 17511038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours amongst injecting drug users in three Afghan cities.
    Nasir A; Todd CS; Stanekzai MR; Bautista CT; Botros BA; Scott PT; Strathdee SA; Tjaden J
    Int J Drug Policy; 2011 Mar; 22(2):145-52. PubMed ID: 21146392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Hepatitis B and C among Drug-Abusing Male Prisoners in Birjand, South Khorasan, Iran.
    Ghafari S; Sharifzadeh G; Jamali S; Taji B; Javadmoosavi SY; Ziaee M
    Arch Iran Med; 2019 Sep; 22(9):501-504. PubMed ID: 31679371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV seropositivity was related to HBsAg seropositivity among injecting drug users in Taiwan.
    Hsieh MH; Hsieh MY; Huang CF; Yeh ML; Wang SC; Yang JF; Chang K; Lin WR; Lin CY; Chen TC; Huang JF; Dai CY; Tsai JJ; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2016 Feb; 32(2):96-102. PubMed ID: 26944329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coinfection by human immunodeficiency virus, hepatitis B virus and hepatitis C virus in injecting drug users.
    Devi KhS; Singh NB; Singh HL; Singh YM
    J Indian Med Assoc; 2009 Mar; 107(3):144, 146-7. PubMed ID: 19810379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China.
    Chen X; He JM; Ding LS; Zhang GQ; Zou XB; Zheng J
    Arch Virol; 2013 Sep; 158(9):1889-94. PubMed ID: 23553454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review.
    Hajarizadeh B; Kairouz A; Ottaviano S; Ireland J; Willing A; Cunningham E; Webb P; Colledge-Frisby S; Wheeler A; Leung J; Tran LT; Price O; Vickerman P; Farrell M; Hickman M; Dore GJ; Bergenström A; Degenhardt L; Grebely J
    Lancet Glob Health; 2023 Dec; 11(12):e1885-e1898. PubMed ID: 37973339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil.
    Oliveira ML; Bastos FI; Telles PR; Yoshida CF; Schatzmayr HG; Paetzold U; Pauli G; Schreier E
    Braz J Med Biol Res; 1999 Sep; 32(9):1107-14. PubMed ID: 10464387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China.
    Zhou YH; Yao ZH; Liu FL; Li H; Jiang L; Zhu JW; Zheng YT
    PLoS One; 2012; 7(8):e42937. PubMed ID: 22916185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia.
    Shapatava E; Nelson KE; Tsertsvadze T; del Rio C
    Drug Alcohol Depend; 2006 Apr; 82 Suppl 1():S35-8. PubMed ID: 16769443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.